The Chemours Company (CC) Guidance & Earnings Results
On 2026-05-05 The Chemours Company reaffirmed guidance: "Adjusted EBITDA $169M vs $166M YoY…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CCThe Chemours CompanyFollow CC — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- 2.7%
- 52-week
- —
- Next earnings
- 17 Feb, in 116 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 May 26 | Reaffirmed | Adjusted EBITDA $169M vs $166M YoY (+2%) |
| 19 Feb 26 | Mixed | Net sales growth 3-5%, Adjusted EBITDA $800-900M, FCF conversion >25% · full year |
The Chemours Company — questions
- What guidance did The Chemours Company give?
- On 2026-05-05: "Adjusted EBITDA $169M vs $166M YoY (+2%)"
- When does The Chemours Company report earnings?
- The Chemours Company's next earnings report is expected on 2027-02-17.
Every figure on this page comes from The Chemours Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.